Want to have a baby? UK warns against ‘skinny jabs' like Ozempic, Wegovy as animal tests show potential harm to newborns
LONDON, June 5 — The UK's medicine regulator warned Thursday against taking 'skinny jabs' to fight weight loss if trying to get pregnant or while breastfeeding because of their unknown effects on babies.
The Medicines and Healthcare products Regulatory Agency (MHRA) said popular jabs like Ozempic and Wegovy 'must not be taken during pregnancy, while trying to get pregnant, or during breastfeeding'.
It urged women to use 'effective contraception while taking these medicines and, in some cases, for up to two months between stopping the medicine and trying to get pregnant'.
'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible... because there is not enough safety data to know whether taking the medicine could cause harm to the baby,' it added.
Rebecca Reynolds, a professor of metabolic medicine at the University of Edinburgh, said there was 'hardly any available data from human studies' to know if the weight loss drugs were safe in pregnancy.
'The data from animal studies suggests the potential for harm with low birthweight and skeletal abnormalities, though more evidence is needed to assess if there are risks of taking these drugs in humans,' she added.
The MHRA also warned about the impact of another weight-loss and diabetes injection, Mounjaro, on the effectiveness of oral contraception for people who are overweight.
'Therefore, those taking Mounjaro who are overweight and are using an oral form of contraception are advised to also use a non-oral form of contraception,' it said.
Ying Cheong, a consultant in reproductive medicine at the University of Southampton, called the MHRA's advice 'both timely and necessary'.
'Gastrointestinal side-effects such as vomiting and diarrhoea can impair oral contraceptive absorption, increasing the risk of unintended pregnancy,' he said. — AFP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
2 hours ago
- The Sun
Novo's Ozempic, Wegovy linked to rare cases of dangerous eye disorder, EMA says
THE European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition. Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, the regulator said on Friday. The EMA, which started its review in December, said the use of the drugs is linked to about twofold increase in the risk of developing the condition compared to people not taking the medicine. NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma. Studies have linked semaglutide to NAION in the past. But this is the first time a regulator has made the link. Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. A large study of nearly 350,000 diabetics published earlier this year had showed that the risk of developing NAION more than doubled after long-term use of semaglutide, compared to patients taking medicines from other classes. The EMA said it has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials and post-marketing surveillance. It has recommended the drugmaker to update prescribing information for medicines containing semaglutide to include NAION as a side effect with a frequency of 'very rare'.
The Sun
2 hours ago
- The Sun
EMA links Wegovy, Ozempic to rare vision loss risk
THE European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition. Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, the regulator said on Friday. The EMA, which started its review in December, said the use of the drugs is linked to about twofold increase in the risk of developing the condition compared to people not taking the medicine. NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma. Studies have linked semaglutide to NAION in the past. But this is the first time a regulator has made the link. Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. A large study of nearly 350,000 diabetics published earlier this year had showed that the risk of developing NAION more than doubled after long-term use of semaglutide, compared to patients taking medicines from other classes. The EMA said it has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials and post-marketing surveillance. It has recommended the drugmaker to update prescribing information for medicines containing semaglutide to include NAION as a side effect with a frequency of 'very rare'. The U.S. Food and Drug Administration did not immediately respond to a Reuters request for comment.
Malay Mail
7 hours ago
- Malay Mail
EKOUAER Debuts in Monaco as Exclusive VIP Gifting Partner on Titania Yacht
Inside the VIP suites, guests were welcomed with hand-selected EKOUAER loungewear—creating a private, comfortable space to unwind between events. Every guest received a thoughtfully curated gift set, offering a lasting reminder of Monaco's signature softness and ease. MONTE CARLO, MONACO - Media OutReach Newswire - 6 June 2025 - During the 2025 Monaco Grand Prix, EKOUAER debuted as the Exclusive VIP Gifting Partner aboard the Titania yacht—a milestone in its evolution from trusted loungewear brand to symbol of modern, elevated luxury. Against the backdrop of one of motorsport's most prestigious events, EKOUAER shared its vision: that comfort and elegance can seamlessly coexist. Guests aboard Titania were invited to experience this philosophy firsthand through pieces that reflect the brand's core values—softness, simplicity, and quiet the weekend, the Titania yacht—moored at Port Hercules with views of the circuit—served as a serene escape from the high-energy race atmosphere. EKOUAER outfitted the yacht's VIP suites with curated selections of its signature loungewear, offering guests a tactile introduction to its philosophy: relaxed refinement suited for both private and elevated included the Satin Silky Pajama Set, a lightweight two-piece with a button-down top and wide-leg pants, ideal for sleep or stylish lounging. The Classic Satin Pajama Set featured timeless piping and tailored lines, perfect for layering or unwinding. For warmer moments, the Satin Top and Shorts Set combined long sleeves with breezy shorts for a polished yet relaxed the exclusive partner aboard Titania, EKOUAER brought its signature take on effortless luxury to life during the Monaco Grand Prix:Throughout the weekend, guests praised EKOUAER's pieces for their softness and breathability, offering instant comfort after a day of social events and race-day boundaries between fashion, lifestyle, and wellness continue to dissolve, EKOUAER stands at the forefront of a cultural shift: where what we wear is not just about how we look, but how we bringing its signature loungewear to one of the world's most prestigious stages, EKOUAER challenges the conventional limits of comfort wear. No longer reserved for the home, its pieces speak to a new standard—where elegance is effortless, intention is inherent, and luxury is measured by how it makes you #EKOUAER The issuer is solely responsible for the content of this announcement.
